Clinical Trial Update: Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2 [Phase 3]

View source ↗

Summary

Phase 3 study of BI 207127 in combination with faldaprevir and ribavirin for hepatitis C, including peginterferon-ineligible patients; results were posted in Fe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BI 207127 (BI-207127)
• Faldaprevir (faldaprevir)
• Ribavirin (ribavirin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hepatitis C, Chronic | Phase 3 | Status: COMPLETED | Results posted: 2016-02-12